These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22130958)

  • 21. Vascular calcification is not related to serum fetuin-A and osteopontin levels in hemodialysis patients.
    Ulutas O; Taskapan MC; Dogan A; Baysal T; Taskapan H
    Int Urol Nephrol; 2018 Jan; 50(1):137-142. PubMed ID: 29134617
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The calcitonin-calcium relation curve and calcitonin secretory parameters in renal patients with variable degrees of renal function.
    Messa P; Mioni G; Turrin D; Guerra UP
    Nephrol Dial Transplant; 1995 Dec; 10(12):2259-65. PubMed ID: 8808222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.
    Massart A; Debelle FD; Racapé J; Gervy C; Husson C; Dhaene M; Wissing KM; Nortier JL
    Am J Kidney Dis; 2014 Nov; 64(5):696-705. PubMed ID: 24856872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease.
    Lishmanov A; Dorairajan S; Pak Y; Chaudhary K; Chockalingam A
    Int Urol Nephrol; 2012 Apr; 44(2):541-7. PubMed ID: 21327525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease.
    Masai H; Joki N; Sugi K; Moroi M
    Atherosclerosis; 2013 Jan; 226(1):228-33. PubMed ID: 23137826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Circulating bone turnover markers and their relationships in hemodialysis patients with vitamin D deficiency].
    Kulicki P; Żebrowski P; Sokalski A; Klatko W; Birecka M; Mieczkowski M; Niemczyk S; Małyszko J; Matuszkiewicz-Rowińska J
    Wiad Lek; 2019; 72(11 cz 2):2202-2209. PubMed ID: 31860837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F; Mawad H; El-Husseini AA; Davenport DL; Malluche HH
    Clin Nephrol; 2019 Apr; 91(4):222-230. PubMed ID: 30862350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease.
    Tuñón J; Fernández-Fernández B; Carda R; Pello AM; Cristóbal C; Tarín N; Aceña Á; González-Casaus ML; Huelmos A; Alonso J; Lorenzo Ó; González-Parra E; Hernández-González I; Mahíllo-Fernández I; López-Bescós L; Egido J
    Diabetes Metab Res Rev; 2016 Oct; 32(7):685-693. PubMed ID: 26888181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of bone metabolism markers with coronary atherosclerosis and coronary artery disease in postmenopausal women.
    Ling Y; Wang Z; Wu B; Gao X
    J Bone Miner Metab; 2018 May; 36(3):352-363. PubMed ID: 28642975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.
    Young A; Hodsman AB; Boudville N; Geddes C; Gill J; Goltzman D; Jassal SV; Klarenbach S; Knoll G; Muirhead N; Prasad GV; Treleaven D; Garg AX;
    Am J Kidney Dis; 2012 Jun; 59(6):761-9. PubMed ID: 22093959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM; Schlieper G; Heussen N; Holzmann S; Busch B; Evenepoel P; Vanholder R; Meijers B; Meert N; Fassbender WJ; Floege J; Jahnen-Dechent W; Ketteler M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2672-9. PubMed ID: 20172849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblast Growth Factor-23 and Vitamin D Metabolism in Subjects with eGFR ≥60 ml/min/1.73 m².
    Nakatani S; Nakatani A; Tsugawa N; Yamada S; Mori K; Imanishi Y; Ishimura E; Okano T; Inaba M
    Nephron; 2015; 130(2):119-26. PubMed ID: 26068724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sun exposure influences the prognostic power of components of mineral metabolism in patients with coronary artery disease.
    Aceña A; Franco-Peláez JA; Gutierrez-Landaluce C; Pello AM; Cristóbal C; Tarín N; Huelmos A; Carda R; Martín-Mariscal ML; Alonso J; González-Parra E; González-Casaus ML; Lorenzo Ó; López Bescos L; Egido J; Tuñón J
    Nutr Metab Cardiovasc Dis; 2017 Sep; 27(9):762-767. PubMed ID: 28803689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineral and bone disorder and longterm survival in a chronic kidney disease grade 3b-4cohort.
    Rios P; Silvariño R; Sola L; Ferreiro A; Lamadrid V; Fajardo L; Gadola L
    Ren Fail; 2022 Dec; 44(1):1356-1367. PubMed ID: 35946486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
    Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of serum FGF-23, MGP and fetuin-A on calcium-phosphate metabolism in maintenance hemodialysis patients.
    Xiao DM; Wu Q; Fan WF; Ye XW; Niu JY; Gu Y
    Hemodial Int; 2013 Oct; 17(4):483-92. PubMed ID: 23490272
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between the Serum Uric Acid Level and the Severity of Coronary Artery Disease in a Retrospective Study of China Nondialysis CKD Patients.
    Yang Y; Lin LH; Gao M; Tang RN; Ma KL; Tu Y; Liu H; Liu BC
    Metab Syndr Relat Disord; 2020 May; 18(4):206-211. PubMed ID: 32069163
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Bioavailable and Free 25-Hydroxyvitamin D Levels, but Not Its Total Level, Are Associated With the Risk of Mortality in Patients With Coronary Artery Disease.
    Yu C; Xue H; Wang L; Chen Q; Chen X; Zhang Y; Hu G; Ling W
    Circ Res; 2018 Sep; 123(8):996-1007. PubMed ID: 30355032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.